Press Releases Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
7.9 ^USD	-7.17%		-1.99%	+28.66%

Jun. 11	Solid Biosciences Inc. Announces Board Resignations	CI
May. 15	Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jun. 04	AQ
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results	May. 15	AQ
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting	May. 07	AQ
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 02	AQ
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	AQ
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	Apr. 01	AQ
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium	Mar. 27	AQ
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results	Mar. 13	AQ
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD	Mar. 07	AQ
Solid Biosciences to Participate at Upcoming Investor Conferences	Mar. 06	AQ
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	Jan. 16	AQ
Solid Biosciences Announces $109 Million Private Placement	Jan. 08	AQ
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	AQ
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003	Dec. 07	AQ
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference	Nov. 22	AQ
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	Nov. 14	AQ
Solid Biosciences to Participate at Jefferies London Healthcare Conference	Nov. 09	AQ
Solid Biosciences Provides Third Quarter Business Update and Financial Results	Nov. 08	AQ
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer	23-10-02	AQ
Solid Biosciences to Participate at Upcoming Investor Conferences	23-09-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Press Releases

Filters